Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bath & Body Works Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Bath & Body Works Inc trades at $20.33 (market cap $4.10B). The key difference: Bath & Body Works Inc is far larger — about 5× Amphastar Pharmaceuticals Inc's market cap, and Bath & Body Works Inc pays a 3.94% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BBWI | |
|---|---|---|
Market Cap | $826.08M | $4.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $33.11 |
52-Week Low | $16.87 | $14.85 |
Enterprise Value | $1.22B | $7.99B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
BBWI trades at $20.33, up 2.01% today, with a bearish technical signal but neutral oscillators. The stock shows strong profitability with a net margin of 10.03% and attractive valuation ratios, including a P/E of 5.78. Recent earnings beat expectations in Q1 2026, and the company's partnership with Ulta Beauty aims to expand reach. Cash flow trends indicate improving net cash flow by 2026, though the balance sheet carries significant debt.
The outlook is mixed: analyst consensus is a Buy with a $22.00 price target, suggesting upside, but risks include declining revenue over five years and high leverage. The Ulta partnership and cost-saving initiatives offer growth potential, yet competitive pressures and macroeconomic headwinds pose challenges for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
